FinancialBuzz.com’s latest


The Buzz


Show: Featuring Our Corporate News Recap on “Cumberland Pharmaceuticals Inc.


Receives FDA Approval to Expand Labeling


for Caldolor to Include Pre-Operative Administration”

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)



surged over 86% in premarket trading after the FDA  approved expanded labeling for Caldolor to now include use in pre-operative administration.

The non-narcotic pain reliever may now be administered just prior to surgery, with a study of orthopedic surgical pain confirming a significant pain reduction when the product was administered every six hours.

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of        high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments.

For more information, please visit:


Cumberland Pharmaceuticals Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post

“The Buzz” Show: Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) FDA Approval for Caldolor

first appeared on

Financial Buzz

.

For further details see:

“The Buzz” Show: Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) FDA Approval for Caldolor